NYSEAMERICAN:HEB Hemispherx BioPharma (HEB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Hemispherx BioPharma Stock (NYSEAMERICAN:HEB) Get Hemispherx BioPharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range$6.70▼$6.7052-Week Range N/AVolume7,639 shsAverage Volume102,599 shsMarket Capitalization$16.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Hemispherx BioPharma, Inc. (NYSEAMERICAN:HEB) is a U.S.-based biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of viral infections, cancers and immune system disorders. The company’s research centers on harnessing the body’s innate immune response to address diseases that currently lack broadly effective treatments. Hemispherx’s principal commercial product is Alferon N Injection, an antiviral drug indicated for the treatment of external genital warts. Its lead investigational candidate is Ampligen® (rintatolimod), a synthetic RNA molecule designed as a toll-like receptor 3 agonist. Ampligen has been studied in conditions such as chronic fatigue syndrome (myalgic encephalomyelitis) and certain malignancies, and the company continues to advance clinical programs and regulatory activities around this immune-modulating therapy. Headquartered in Philadelphia, Pennsylvania, Hemispherx BioPharma operates primarily in the United States while pursuing strategic collaborations and regulatory approvals internationally. The company is led by President and Chief Executive Officer Thomas G. Equels, under whose guidance Hemispherx engages with government agencies, academic research centers and commercial partners to support its pipeline and expand its therapeutic reach.AI Generated. May Contain Errors. Read More Receive HEB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemispherx BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HEB Stock News HeadlinesHemispherx BioPharma (NYSEAMERICAN:HEB) Stock Price Crosses Above 200 Day Moving Average - Time to Sell?May 23 at 2:47 AM | americanbankingnews.comHemispherx BioPharma (NYSEAMERICAN:HEB) Share Price Crosses Above 200 Day Moving Average - Here's WhyMay 15, 2026 | americanbankingnews.comPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 24 at 1:00 AM | Porter & Company (Ad)Hamilton ETFs Announces Name Changes for HEB and MIXMay 4, 2026 | businesswire.comHamilton ETFs Launches Hamilton Canadian Financials Index ETFJanuary 20, 2025 | businesswire.comH-E-B’s affordable grocery chain Joe V’s Smart Shop is coming to IrvingAugust 10, 2024 | dallasnews.comDHemispherx Biopharma earnings preview: what Wall Street is expectingMay 15, 2024 | markets.businessinsider.comH-E-B hosting hiring fairsJanuary 7, 2024 | cbsnews.comSee More Headlines HEB Stock Analysis - Frequently Asked Questions How were Hemispherx BioPharma's earnings last quarter? Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) released its quarterly earnings data on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.70) by $0.63. The specialty pharmaceutical company had revenue of $0.03 million for the quarter. When did Hemispherx BioPharma's stock split? Hemispherx BioPharma's stock reverse split before market open on Tuesday, June 11th 2019.The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 10th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Hemispherx BioPharma? Shares of HEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Hemispherx BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hemispherx BioPharma investors own include Goodrich Petroleum (GDPMQ), Inovio Pharmaceuticals (INO), Palatin Technologies (PTN) and Ayala Pharmaceuticals (ADXS). Company Calendar Last Earnings8/15/2019Today5/24/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEAMERICAN:HEB Previous SymbolNYSE:HEB CIK946644 Webwww.hemispherx.net Phone+1-407-2718516FaxN/AEmployees31Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares2,442,000Free FloatN/AMarket Cap$16.36 million OptionableNot Optionable BetaN/A Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NYSEAMERICAN:HEB) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemispherx BioPharma, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemispherx BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
